(Reuters) -AstraZeneca’s experimental drug baxdrostat significantly lowered blood pressure during a 24-hour window of monitoring in a late-stage trial of patients with treatment-resistant hypertension, it said on Tuesday.

The company said the drug met the main goal of the study when compared to placebo at the end of 12 weeks. Patients in the trial had received 2 milligrams of baxdrostat or placebo on top of standard care.

The Anglo-Swedish drugmaker has previously said that it expects to file for regulatory approval for baxdrostat before year-end and sees peak annual sales for the drug topping $5 billion.

Baxdrostat targets blood pressure-regulating hormone aldosterone, a novel approach compared with older treatments like diuretics and ACE inhibitors, which do not address hormonal drive

See Full Page